Small-cap mutual funds ramped up exposure to industrial products and pharmaceutical stocks in May 2026, with Vijaya ...

Care Ratings expects Dr Lal PathLabs' revenue to grow by 11-12 per cent per annum in the near-to-medium term driven by ...

Earnings call Dr. Lal PathLabs reported Q2 FY26 revenue of ₹731 crore, up 10.7% YoY, with PAT rising 16.4% to ₹152 crore and EBITDA margin stable at 30.7%. Management reaffirmed FY26 revenue growth ...

Ex-Dividend Stocks: A total of 17 stocks, including LIC, IndusInd Bank, Supreme Industries, Dr Lal PathLabs and CARE Ratings, ...

April 25 (Reuters) - Dr Lal Path Labs (DLPA.NS), opens new tab, India's largest diagnostics firm by revenue, reported fourth-quarter profit above expectations on Friday as strong demand for its ...

Here's an analysis of the annual report of DR. LAL PATHLABS for 2024-25. It includes a full income statement, balance sheet and cash flow analysis of DR. LAL PATHLABS. Also includes updates on the ...

Jan 30 (Reuters) - India's Dr Lal Path Labs (DLPA.NS), opens new tab reported a 19% jump in its third-quarter profit on Thursday, led by continued demand for its bundle test offerings, sending its ...

Bengaluru: Dr. Lal Path Labs reported a ‍lower third-quarter profit on Friday after taking a one-time charge ⁠linked to India's new labour code, despite strong demand for its bundled test packages.

Stocks to buy for short term: Market benchmarks the Sensex and the Nifty 50 clocked a healthy gain of 1.6 per cent for the week ended November 14, driven by hopes of an India-US trade deal amid better ...

Earnings call Dr. Lal PathLabs delivered Q3 FY26 revenue growth of 10.6% YoY to INR 660 crore, with EBITDA before exceptionals up 16.3% and a margin of 27.2%. Patient volume growth was modest at 2.7% ...